

Todd A Alonzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5636869/publications.pdf>

Version: 2024-02-01

194
papers

4,939
citations

147786

31
h-index

102480

66
g-index

197
all docs

197
docs citations

197
times ranked

5741
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia. <i>JAMA Oncology</i> , 2022, 8, 79.	7.1	36
2	CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 252-261.	1.6	18
3	Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. <i>Cancers</i> , 2022, 14, 616.	3.7	4
4	Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance?. <i>Pediatric Blood and Cancer</i> , 2022, , e29613.	1.5	1
5	Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute's Children's Oncology Group Pediatric MATCH Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2224-2234.	1.6	45
6	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2235-2245.	1.6	21
7	The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 630-634.	3.5	29
8	Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28946.	1.5	3
9	Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. <i>Cancers</i> , 2021, 13, 2336.	3.7	30
10	<i>CEBPA</i> Zip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. <i>Blood</i> , 2021, 138, 1137-1147.	1.4	55
11	High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. <i>Blood</i> , 2021, 138, 2337-2346.	1.4	16
12	Cancer Informatics for Cancer Centers: Scientific Drivers for Informatics, Data Science, and Care in Pediatric, Adolescent, and Young Adult Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 881-896.	2.1	3
13	Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF- κ B subunit RelA. <i>Proteomics - Clinical Applications</i> , 2021, , 2100072.	1.6	4
14	<i>KMT2A</i> Partial Tandem Duplications (<i>KMT2A</i> -PTD) Is a Rare, but Recurrent Genomic Event in Childhood AML and Associated with High Rate of Co-Occurring <i>FLT3</i> Mutations. <i>Blood</i> , 2021, 138, 609-609.	1.4	0
15	ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications. <i>Blood</i> , 2021, 138, 2356-2356.	1.4	4
16	Significant Improvements in Survival for Patients with t(6;9)(p23;q34)/ <i>DEK-NUP214</i> in Contemporary Trials with Intensification of Therapy: A Report from the Children's Oncology Group. <i>Blood</i> , 2021, 138, 519-519.	1.4	3
17	Epigenetic Silencing of CD34 in AML and Association with Outcome in <i>KMT2A</i> Fusions. <i>Blood</i> , 2021, 138, 802-802.	1.4	0
18	Gene Expression Analysis of CML Patients across the Age Spectrum. <i>Blood</i> , 2021, 138, 1473-1473.	1.4	0

#	ARTICLE	IF	CITATIONS
19	EZH2-Mediated MHC Class II Silencing Drives Immune Evasion in AML with t(16;21) (<i>FUS-ERG</i>). Blood, 2021, 138, 374-374.	1.4	0
20	Integrated Genomic Analysis Identifies UBTF Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia. Blood, 2021, 138, LBA-4-LBA-4.	1.4	0
21	Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers, 2021, 13, 6263.	3.7	7
22	Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431. Archives of Pathology and Laboratory Medicine, 2020, 144, 466-472.	2.5	9
23	Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Cytometry Part B - Clinical Cytometry, 2020, 98, 52-56.	1.5	17
24	Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer, 2020, 126, 593-601.	4.1	32
25	A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study. Biology of Blood and Marrow Transplantation, 2020, 26, 712-717.	2.0	8
26	Adaptive trial designs in diagnostic accuracy research. Statistics in Medicine, 2020, 39, 591-601.	1.6	11
27	Morphologic remission status is limited compared to \hat{P}^N flow cytometry: a Children's Oncology Group AAML0531 report. Blood Advances, 2020, 4, 5050-5061.	5.2	21
28	Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing-Based Cervical Screen-and-Treat Program in El Salvador. JCO Global Oncology, 2020, 6, 1519-1530.	1.8	12
29	Acute erythroid leukemia is enriched in <i>NUP98</i> fusions: a report from the Children's Oncology Group. Blood Advances, 2020, 4, 6000-6008.	5.2	11
30	Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2020, 38, 2170-2177.	1.6	35
31	Information fraction estimation based on the number of events within the standard treatment regimen. Biometrical Journal, 2020, 62, 1960-1972.	1.0	4
32	Comprehensive Transcriptome Profiling of Cryptic <i>CBFA2T3</i> - <i>GLIS2</i> Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study. Clinical Cancer Research, 2020, 26, 726-737.	7.0	42
33	Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia. Blood, 2020, 136, 38-39.	1.4	3
34	Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol. Blood, 2020, 136, 39-39.	1.4	1
35	Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Blood, 2020, 136, 39-40.	1.4	1
36	Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia. Blood, 2020, 136, 28-29.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts. <i>Blood</i> , 2020, 136, 20-21.	1.4	1
38	Comparisons of New HIV Rapid Test Kit Performance. <i>AIDS and Behavior</i> , 2019, 23, 313-317.	2.7	4
39	ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial. <i>Blood Cancer Journal</i> , 2019, 9, 51.	6.2	26
40	Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27700.	1.5	6
41	Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 51-55.	0.6	20
42	Evaluating the predictive value of measures of susceptibility to tobacco and alternative tobacco products. <i>Addictive Behaviors</i> , 2019, 96, 50-55.	3.0	16
43	Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML. <i>Blood</i> , 2019, 134, 3772-3772.	1.4	7
44	Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2019, 134, 459-459.	1.4	6
45	Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study. <i>Blood</i> , 2019, 134, 461-461.	1.4	12
46	High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction. <i>Blood</i> , 2019, 134, 118-118.	1.4	3
47	Response to Sorafenib in FLT3/ITD AML Is Dependent on Co-Occurring Mutational Profile. <i>Blood</i> , 2019, 134, 119-119.	1.4	6
48	Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031. <i>Blood</i> , 2019, 134, 292-292.	1.4	19
49	Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2019, 134, 703-703.	1.4	1
50	Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial. <i>Blood</i> , 2019, 134, 2676-2676.	1.4	0
51	Estimation of the volume under the receiver-operating characteristic surface adjusting for non-ignorable verification bias. <i>Statistical Methods in Medical Research</i> , 2018, 27, 715-739.	1.5	4
52	The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. <i>Nature Medicine</i> , 2018, 24, 103-112.	30.7	525
53	Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. <i>Blood</i> , 2018, 132, 1584-1592.	1.4	45
54	Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2017, 23, 3649-3656.	7.0	21

#	ARTICLE	IF	CITATIONS
55	Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. <i>Blood</i> , 2017, 129, 3051-3058.	1.4	19
56	Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26612.	1.5	33
57	Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. <i>Blood</i> , 2017, 129, 3304-3313.	1.4	71
58	Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531. <i>Haematologica</i> , 2017, 102, 2058-2068.	3.5	22
59	Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. <i>Blood</i> , 2017, 130, 943-945.	1.4	16
60	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2017, 102, e340-e343.	3.5	4
61	Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2017, 176, 86-91.	2.5	29
62	Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. <i>Journal of Clinical Oncology</i> , 2017, 35, 3021-3029.	1.6	62
63	CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2017, 35, 2674-2682.	1.6	120
64	Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Children's Oncology Group report. <i>Oncotarget</i> , 2017, 8, 90037-90049.	1.8	5
65	Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2017, 130, 883-883.	1.4	2
66	Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group. <i>Frontiers in Genetics</i> , 2016, 7, 139.	2.3	2
67	Adapting CryoPen, a Non-Gas Based Cryotherapy System for Use in Low- and Middle-Income Countries. <i>Journal of Global Oncology</i> , 2016, 2, 11s-12s.	0.5	1
68	Inverse probability weighting estimation of the volume under the ROC surface in the presence of verification bias. <i>Biometrical Journal</i> , 2016, 58, 1338-1356.	1.0	5
69	Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group. <i>International Journal of Cancer</i> , 2016, 139, 1930-1935.	5.1	7
70	Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. <i>Cancer Medicine</i> , 2016, 5, 2412-2416.	2.8	4
71	Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. <i>Blood</i> , 2016, 127, 3424-3430.	1.4	79
72	CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. <i>Blood</i> , 2016, 127, 3094-3098.	1.4	49

#	ARTICLE	IF	CITATIONS
73	Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 82.	17.0	22
74	miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2096-2103.	1.5	21
75	Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 3766-3772.	1.6	17
76	CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2016, 34, 747-755.	1.6	116
77	Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2016, 22, 1951-1957.	7.0	49
78	Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. <i>Cancer Research</i> , 2016, 76, 2197-2205.	0.9	133
79	A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. <i>Leukemia and Lymphoma</i> , 2016, 57, 1567-1574.	1.3	13
80	Prognostic Significance of 11q23/MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531. <i>Blood</i> , 2016, 128, 1211-1211.	1.4	14
81	Excess Treatment-Related Mortality in Obese Children and Adolescents with Acute Myeloid Leukemia on AAML0531: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 2790-2790.	1.4	1
82	Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative. <i>Blood</i> , 2016, 128, 2873-2873.	1.4	5
83	FLT3 Mutations in Pediatric Acute Promyelocytic Leukemia; A Report from the Children's Oncology Group AAML0631 Trial. <i>Blood</i> , 2016, 128, 2884-2884.	1.4	2
84	The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 899-899.	1.4	10
85	Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 2846-2846.	1.4	2
86	CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study. <i>Blood</i> , 2016, 128, 2743-2743.	1.4	0
87	Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 2794-2794.	1.4	0
88	The Effect of Traumatic Diagnostic Lumbar Puncture in De Novo Pediatric Acute Myeloid Leukemia - a Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 4016-4016.	1.4	0
89	Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration. <i>Blood</i> , 2016, 128, 1687-1687.	1.4	1
90	A microRNA Expression-Based Model Predicts Event Free Survival in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1210-1210.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1184-1189.	1.5	12
92	Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 629-636.	1.5	43
93	Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. <i>Blood</i> , 2015, 125, 516-524.	1.4	69
94	Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2015, 100, e496-e500.	3.5	3
95	Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2015, 208, 408-413.	0.4	3
96	Multimerin-1 (<i>MMRN1</i>) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2015, 21, 3187-3195.	7.0	18
97	The genomic landscape of juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2015, 47, 1326-1333.	21.4	233
98	Comparison of Rapid Point-of-Care Tests for Detection of Antibodies to Hepatitis C Virus. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv101.	0.9	23
99	Rearrangements in Nucleoporin Family of Genes in Childhood Acute Myeloid Leukemia: A Report from Children Oncology Group and NCI/COG Target AML Initiative. <i>Blood</i> , 2015, 126, 169-169.	1.4	2
100	Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631. <i>Blood</i> , 2015, 126, 219-219.	1.4	3
101	ASXL1 and ASXL2 Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative. <i>Blood</i> , 2015, 126, 2587-2587.	1.4	1
102	Prognostic Relevance of Recurrent Genetic Aberrations in Pediatric Acute Megakaryoblastic Leukemia. <i>Blood</i> , 2015, 126, 2598-2598.	1.4	1
103	Heirarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531. <i>Blood</i> , 2015, 126, 561-561.	1.4	3
104	Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated with Treatment Resistance - a Report from the COG/NCI-Target AML Initiative. <i>Blood</i> , 2015, 126, 687-687.	1.4	2
105	Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative. <i>Blood</i> , 2015, 126, 87-87.	1.4	19
106	Patient-Reported Outcome Coordinator Did Not Improve Quality of Life Assessment Response Rates: A Report from the Children's Oncology Group. <i>PLoS ONE</i> , 2015, 10, e0125290.	2.5	10
107	Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. <i>PLoS ONE</i> , 2015, 10, e0143480.	2.5	16
108	TET2 Mutations Are Highly Associated with RUNX1-RUNX1T1 Translocations and NPMc+ in Childhood AML: a Report from Children's Oncology Group AAML03P1, AAML0531 and NCI/COG Target AML Initiative. <i>Blood</i> , 2015, 126, 1368-1368.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Genetic Variations in Calicheamicin Pathway Genes Are Predictors of Gemtuzumab Ozogamicin Response in AML Patients: Results from COG-AAML0531 Study. <i>Blood</i> , 2015, 126, 1260-1260.	1.4	0
110	Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106. <i>Blood</i> , 2015, 126, 2576-2576.	1.4	0
111	Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 88-88.	1.4	0
112	Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative. <i>Blood</i> , 2015, 126, 170-170.	1.4	0
113	Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2014, 32, 3021-3032.	1.6	360
114	Acute myeloid leukaemia (<sc>AML</sc>) with t(6;9)(p23;q34) is associated with poor outcome in childhood <sc>AML</sc> regardless of <i>FLT3</i> <i>ITD</i> status: a report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2014, 166, 254-259.	2.5	58
115	NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. <i>Blood</i> , 2014, 124, 2400-2407.	1.4	99
116	Multimerin-1 (MMRN1) As Novel Adverse Prognostic Marker in Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2014, 124, 2330-2330.	1.4	0
117	Patient Factors Associated with Enrollment on an Acute Myeloid Leukemia Phase III Clinical Trial: A Report from the Children's Oncology Group. <i>Blood</i> , 2014, 124, 2286-2286.	1.4	0
118	Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3-ITD+ Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2014, 124, 486-486.	1.4	0
119	Disease Characteristics and Prognostic Implications Of Cell Surface FLT3 Receptor (CD135) Expression In Pediatric Acute Myeloid Leukemia – A Report From Children's Oncology Group. <i>Blood</i> , 2013, 122, 2609-2609.	1.4	1
120	Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Children's Oncology Group. <i>Blood</i> , 2013, 122, 491-491.	1.4	40
121	Impact Of Residual Disease On Survival In Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation For Acute Myeloid Leukemia In First Complete Remission. <i>Blood</i> , 2013, 122, 65-65.	1.4	3
122	Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group. <i>Blood</i> , 2013, 122, 931-931.	1.4	1
123	PIM3-SC02 Fusion Is a Novel Transcription-Induced Chimera That Is Highly Prevalent In Childhood AML. <i>Blood</i> , 2013, 122, 2549-2549.	1.4	3
124	Genomic Architecture and Treatment Response In Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group. <i>Blood</i> , 2013, 122, 610-610.	1.4	0
125	Constitutional Telomerase-Associated Gene Variants In Pediatric Acute Myeloid Leukemia (AML) and In Association With Chemotherapy-Related Toxicities. <i>Blood</i> , 2013, 122, 1310-1310.	1.4	0
126	NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children's Oncology Group and SWOG. <i>Blood</i> , 2013, 122, 488-488.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Duration Of Neutropenia Is Associated With Reduced Relapse Risk In Children With De Novo Acute Myeloid Leukemia: A Report From The Children's Oncology Group. Blood, 2013, 122, 2650-2650.	1.4	0
128	Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood, 2012, 120, 1581-1588.	1.4	256
129	AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia. Cancer, 2012, 118, 761-769.	4.1	157
130	Identification of Novel Somatic Mutations, Regions of Recurrent Loss of Heterozygosity (LOH) and Significant Clonal Evolution From Diagnosis to Relapse in Childhood AML Determined by Exome Capture Sequencing " an NCI/COG Target AML Study. Blood, 2012, 120, 123-123.	1.4	2
131	WT1 snp rs16754 Genotype Predicts Treatment Related Mortality (TRM) in African-American and Asian Pediatric AML Patients: A Report From the Children's Oncology Group. Blood, 2012, 120, 1385-1385.	1.4	1
132	A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia: A Children's Oncology Group (COG) Study. Blood, 2012, 120, 3580-3580.	1.4	4
133	RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia. Blood, 2012, 120, 1278-1278.	1.4	0
134	Effectiveness of Supportive Care Measurements to Reduce Infections During Induction for Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Blood, 2012, 120, 1478-1478.	1.4	0
135	Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group.. Blood, 2012, 120, 2388-2388.	1.4	0
136	Expression of RUNX1 and RUNX1T1 Correlates with Cytogenetic Subgroups in Pediatric AML: A Report From the Children's Oncology Group. Blood, 2012, 120, 1425-1425.	1.4	0
137	Constitutional Telomerase-Associated Gene Variants Associated with Chemotherapy-Related Toxicities in Pediatric Acute Myeloid Leukemia (AML). Blood, 2012, 120, 1403-1403.	1.4	0
138	Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group. Blood, 2012, 120, 529-529.	1.4	0
139	Novel IRF8 Splice Variants Are Validated As a New Prognostic Biomarker for Adverse Outcome in an Independent Population of Pediatric Patients with AML.. Blood, 2012, 120, 2550-2550.	1.4	0
140	AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia. Blood, 2012, 120, 3604-3604.	1.4	0
141	Hematopoietic Cell Transplant Versus Chemotherapy As Consolidation Treatment for Pediatric AML with Poor-Risk Cytogenetics. Blood, 2012, 120, 127-127.	1.4	0
142	High EVI1 expression Is Associated with MLL rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children's Oncology Group.. Blood, 2012, 120, 2530-2530.	1.4	0
143	Outcome of Pediatric Patients with Acute Myeloid Leukemia and -5/5q-Abnormalities Enrolled On Five Children's Oncology Group Acute Myeloid Leukemia Treatment Protocols. Blood, 2012, 120, 1414-1414.	1.4	0
144	Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Munster AML Study Group.. Blood, 2012, 120, 2516-2516.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Novel IL23R Splice Variant Is Associated with Worse Prognosis in Pediatric Patients with AML. Blood, 2012, 120, 2546-2546.	1.4	0
146	Acute Myeloid Leukemia with t(6;9)(p23;q34) Is Associated Poor Outcome in Childhood AML Regardless of FLT3/ITD Status, A Report From Children's Oncology Group. Blood, 2012, 120, 2541-2541.	1.4	2
147	Leukemic mutations in the methylation-associated genes <i>DNMT3A</i> and <i>IDH2</i> are rare events in pediatric AML: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2011, 57, 204-209.	1.5	109
148	Bias in estimating accuracy of a binary screening test with differential disease verification. Statistics in Medicine, 2011, 30, 1852-1864.	1.6	11
149	Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results. Blood, 2011, 118, 3544-3544.	1.4	1
150	Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group. Blood, 2011, 118, 3545-3545.	1.4	1
151	FACS Analysis of Stat3/5 Signaling Reveals Ligand Sensitivity As a Significant Prognostic Factor in Pediatric AML: A Children's Oncology Group Report. Blood, 2011, 118, 938-938.	1.4	1
152	Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531. Blood, 2011, 118, 939-939.	1.4	4
153	Clinical Significance of CD33 Non-Synonymous Single Nucleotide Polymorphisms (SNPs) in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozogamicin-Containing Chemotherapy. Blood, 2011, 118, 3489-3489.	1.4	4
154	The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Blood, 2011, 118, 3555-3555.	1.4	0
155	Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group. Blood, 2011, 118, 2617-2617.	1.4	0
156	TET2 Mutations Are Associated with Poor Outcome in Pediatric AML: A Report From the Children's Oncology Group. Blood, 2011, 118, 569-569.	1.4	0
157	The Prognostic Effect of High WT1 Gene Expression in Pediatric AML Depends on WT1 SNP rs16754 Status: A Report From the Children's Oncology Group (COG). Blood, 2011, 118, 1444-1444.	1.4	0
158	Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group. Blood, 2010, 116, 1071-1071.	1.4	4
159	Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group. Blood, 2010, 116, 1702-1702.	1.4	1
160	Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531. Blood, 2010, 116, 182-182.	1.4	7
161	Outcome of Adolescents and Young Adults (AYAs) with Non-M3 Acute Myeloid Leukemia (AML) Treated on Children's Oncology Group (COG) Trials Compared to Cancer and Leukemia Group B (CALGB) and Southwest Oncology Group (SWOG) Trials. Blood, 2010, 116, 183-183.	1.4	4
162	Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group. Blood, 2010, 116, 761-761.	1.4	6

#	ARTICLE	IF	CITATIONS
163	TET2 SNP rs2454206 (I1762V) Correlates with Improved Survival In Pediatric Acute Myelogenous Leukemia, a Report From the Children's Oncology Group. Blood, 2010, 116, 949-949.	1.4	4
164	Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421. Blood, 2010, 116, 954-954.	1.4	2
165	Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531. Blood, 2010, 116, 2740-2740.	1.4	0
166	The WT1 synonymous SNP rs16754 Is Associated with Higher mRNA Expression and Predicts Significantly Improved Outcome In Favorable-Risk Pediatric AML: a Report From the Children's Oncology Group. Blood, 2010, 116, 950-950.	1.4	0
167	Association of CD33 Expression Level with Disease Risk-Group Classification and Induction Response In Pediatric AML: A Report From the Children's Oncology Group. Blood, 2010, 116, 2732-2732.	1.4	6
168	Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study. Blood, 2010, 116, 762-762.	1.4	2
169	Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study. Blood, 2010, 116, 2737-2737.	1.4	1
170	High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group.. Blood, 2010, 116, 1072-1072.	1.4	0
171	Multiparameter FACS Analysis of G-CSF and IL-6 Signaling through Stat3 and Stat5 In Primary Pediatric AML Samples.. Blood, 2010, 116, 1051-1051.	1.4	1
172	High Expression of Neutrophil Elastase Predicts Improved Survival In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Blood, 2010, 116, 2762-2762.	1.4	0
173	The Prevalence of Fanconi Anemia Among Patients with De Novo Acute Myelogenous Leukemia. Blood, 2010, 116, 2232-2232.	1.4	0
174	Oxidant Pathway Functional Polymorphisms Influence the Risk of Myeloid Leukemia/Transient Myeloproliferative Disorder In Children with Down Syndrome.. Blood, 2010, 116, 1680-1680.	1.4	0
175	CBL Mutations In Pediatric Acute Myelogenous Leukemia Are a Rare Event, a Report From the Children's Oncology Group.. Blood, 2010, 116, 1659-1659.	1.4	0
176	A comparison of tests for restricted orderings in the three-class case. Statistics in Medicine, 2009, 28, 1144-1158.	1.6	16
177	Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood, 2009, 113, 6558-6566.	1.4	166
178	RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group.. Blood, 2009, 114, 2614-2614.	1.4	2
179	AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.. Blood, 2009, 114, 3076-3076.	1.4	4
180	Pathway Based Evaluation of Cytarabine Pharmacogenetics in Children with Acute Myeloid Leukemia.. Blood, 2009, 114, 2610-2610.	1.4	0

#	ARTICLE	IF	CITATIONS
181	High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.. Blood, 2009, 114, 1592-1592.	1.4	0
182	Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Blood, 2008, 111, 1044-1053.	1.4	259
183	Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants.. Blood, 2008, 112, 2255-2255.	1.4	0
184	Development and Evaluation of Classifiers. Methods in Molecular Biology, 2007, 404, 89-116.	0.9	14
185	Statistical Methods for Evaluating DNA Methylation as a Marker for Early Detection or Prognosis. Disease Markers, 2007, 23, 113-120.	1.3	4
186	Prevalence and Prognostic Implications of CEBPÎ± Mutations in Pediatric AML.. Blood, 2007, 110, 1441-1441.	1.4	0
187	Clinical implications of FLT3 mutations in pediatric AML. Blood, 2006, 108, 3654-3661.	1.4	355
188	Small sample estimation of relative accuracy for binary screening tests. Statistics in Medicine, 2004, 23, 21-34.	1.6	7
189	Estimating disease prevalence in two-phase studies. Biostatistics, 2003, 4, 313-326.	1.5	53
190	Impact of Granulocyte Colony-Stimulating Factor Use During Induction for Acute Myelogenous Leukemia in Children: A Report From the Children's Cancer Group. Journal of Pediatric Hematology/Oncology, 2002, 24, 627-635.	0.6	29
191	Distribution-free ROC analysis using binary regression techniques. Biostatistics, 2002, 3, 421-432.	1.5	172
192	Sample size calculations for comparative studies of medical tests for detecting presence of disease. Statistics in Medicine, 2002, 21, 835-852.	1.6	80
193	Assessing Accuracy of Oral Health Diagnostic Tests. , 0, , 205-218.		0
194	IL-10 and TNFÎ± are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report. Pediatric Hematology and Oncology, 0, , 1-12.	0.8	3